ASGCT 2025: SK pharmteco CEO Recaps Conference Presentations, Networking
The company’s presence at ASGCT included not only a booth on the show floor, but also one oral and nine poster presentations.
At the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, held from May 13–17, 2025 in New Orleans, California-based SK pharmteco presented one oral session, “Leveraging the Qiagen Qiacuity DPCR Platform for Enhanced Viral Quantification, Genome Integrity Analysis, and In-Process Analytics in Gene Therapy and Biomanufacturing,” and had nine posters accepted for display, several of which detailed the company’s work with adeno-associated virus, or AAV, viral vectors.
CEO Joerg Ahlgrimm talked with Pharmaceutical Technology® Group about the company’s goals for networking during the event.
“The more we can work together and move the field forward, ultimately it’s important for patients, and I think if the industry finds ways to work together in many different fields, then we will be able to advance many of those therapies faster and ensure that many of the patients … will be treated at some point in the future. So clearly, that’s important to us,” Ahlgrimm says in the interview. “We also, of course, use the opportunity to showcase our manufacturing and development capabilities, meet people with whom we can work together on technology, but also meet with people where we can provide services or we can foster other collaborations or strategic partnerships, and provide value and find ways to get out to advance therapies toward the patients.”
Click the video above to watch the full interview.
Ahlgrimm is featured in the June issue of BioPharm International®, where he discusses the latest advances in drug substance testing.
Click here for all of PharmTech Group’s coverage of ASGCT 2025.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
